Shortcut Navigation:

Featured Clinical Trials

Learn what’s coming down the research pipeline, and find breast cancer clinical trials you may be eligible to participate in.

Open Trial Tests Oral PARP Inhibitor for BRCA-positive Disease

Researchers seek 306 people with metastatic, HER2-negative breast cancer and who tested positive for either a BRCA1 or BRCA2 mutation to take part in a treatment study. The trial team will assess the survival benefit and safety of niraparib, an oral PARP inhibitor, compared with physicians’ choice of standard chemotherapy.

Impact of Early Surgery for Metastatic Breast Cancer

Researchers seek 880 men and women with metastatic breast cancer who have a primary tumor still in the breast for a study designed to find out if removing it lengthens survival. The primary tumor is the first tumor in the breast. Cancer cells from the primary tumor can spread to other parts of the body, causing metastatic disease.

Study of Combination Chemotherapy Plus Trastuzumab

Researchers from the National Surgical Breast and Bowel Project seek women with early-stage, HER2-low breast cancer for a phase III study. The trial team is exploring whether adding trastuzumab (Herceptin) to combination chemotherapy improves invasive disease-free survival. 

Trial Compares HER2-positive Therapies in People With Early Breast Cancer

Researchers seek participants with early-stage, HER2-positive breast cancer for a phase III study. The trial team will explore which of two anti-HER2 medicines results in the longest invasive disease-free survival.

Phase I Trial to Test New Anti-HER2 Pill

Researchers seek 48 women for a small, phase IB study of ONT-380, a new anti-HER2 medicine that can be taken by mouth. The pill will be given along with the standard amount of T-DM1, by vein.

Trial Tests Antidepressant as Therapy for Treatment-Related Joint Pain

Researchers seek postmenopausal women with hormone-positive breast cancer for a clinical trial exploring whether daily doses of an antidepressant lessens pain related to the use of hormonal therapies, when compared to women who take no pain medicines.

Trial Tests Hormonal Therapy With and Without Chemo for Early-Stage, Invasive Breast Cancer

Researchers seek women diagnosed with invasive, early-stage, hormone-positive breast cancer to enroll in a phase III study. 

Trial Seeks Participants With Metastatic Breast Cancer and BRCA1/2 Mutations

The BROCADE study needs men and women with metastatic breast cancer and a BRCA1 or BRCA2 gene mutation for a phase II clinical trial. The trial team will assess how safe and effective a new targeted therapy is when combined with one or more common chemotherapy medicines.

Women With Metastatic Triple-Negative Breast Cancer Needed for Trial

Researchers seek 240 women with metastatic, triple-negative breast cancer for a phase II study assessing the safety of different chemotherapy combinations and how well they prevent the worsening of the disease. 

BELLE-2 Study Explores Use of PI3K Inhibitor

Postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that continued to grow during or after treatment with an aromatase inhibitor (anastrozole, letrozole, and exemestane) are needed for a clinical trial. Researchers conducting the trial are examining the safety and effectiveness of combining the PI3K inhibitor BMK120 with fulvestrant (Faslodex).

Join Your Community for Yoga on the Steps!

Close
close